Psychedelic Drug Developers Could Benefit From NIH Funding for Chronic Pain
Cybin Inc. CEO to Speak at Milken Global Conference
Cybin to Participate at the 27th Annual Milken Institute Global Conference
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced that Doug Drysdale, Cybin's Chief Executive Officer, will be speaking at the 27th Annual Milken Institute Global Conference on a panel entitled "Collaborating for Improved Mental Health."
Cybin Inc. Unveils Promising Psychedelic Research
Cybin Announces Publication of Research Manuscript in the Journal of Medicinal Chemistry
- Publication explores structure-activity relationships ("SAR") of a broad range of 2C-X analogs - - Innovative research led to the discovery of CYB210010, a potent and long-acting serotonin 5-HT2 receptor agonist
Cedar Clinical Research Selected as Clinical Research Site for Cybin's Phase 3 Study of CYB003
VANCOUVER, BC, April 17, 2024 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing traditional and innovative behaviora
Cybin Inc. Secures Patent, Progresses MDD Therapy
Cybin Announces Grant Of Additional US Patent In Support Of Its CYB003 Breakthrough Therapy Program For Major Depressive Disorder
Cybin Announces Grant Of Additional US Patent In Support Of Its CYB003 Breakthrough Therapy Program For Major Depressive Disorder
Cybin Announces Grant of Additional U.S. Patent in Support of Its CYB003 Breakthrough Therapy Program for Major Depressive Disorder
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced that the United States Patent and Trademark Office has granted U.S. patent 11,958,807 in support of its CYB003 program in Major Depressive Disorder ("MDD").
Cybin to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
Cybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic
Psychedelics Headlines: A Form Of Life, Treating Chronic Pain, Microdosing And More
Welcome to Benzinga's psychedelic headlines roundup. This is our pick of must-read news items from the last two weeks of March 2024.See previous edition Psychedelics Headlines: Substitution Survey, Fr
Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More
FDA Grants Cybin Breakthrough Therapy Status For Major Depression Psilocybin Therapy, Company Announces Positive Clinical Data & Canadian $150M Private PlacementClinical-stage psychedelics biopharma c
Cybin Inc. Secures $150M for Psychedelic Research
Cybin Announces Closing of the Oversubscribed Private Placement of U.S. $150 Million
Cybin (CYBN) Begins Phase II Study on Anxiety Drug, Stock Up
Cybin, Inc. Shines at Dallas Investor Event
Cybin to Present at Public Ventures Discovery Day on March 19th in Dallas
Cybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation
Cybin Initiates Phase 2 Study for Psychedelic Drug DMT
Cybin Inc. Advances Novel Anxiety Treatment
Cybin Says It Initiated Phase 2 Proof-of-Concept Study Of CYB004 In Generalized Anxiety Disorder
Cybin Says It Initiated Phase 2 Proof-of-Concept Study Of CYB004 In Generalized Anxiety Disorder
No Data